Prevention of Bim phosphorylation and degradation; promotion of DNA damage; targeting myeloma stem cells; anti-angiogenesis; disrupting Ras farnesylation; activation of SEK1/JNK pathway. This evidence concerns the gene MAP2K4 and plasma cell myeloma.